http://lifestyle.matomyseo.com/

Author: Ractigen Therapeutics

Ractigen Therapeutics Presents Positive Phase I Data for RAG-17 in SOD1-ALS at the 2026 AAN Annual Meeting, Demonstrating 81% Reduction in Neurofilament Light Chain

April 21, 2026
Ractigen Therapeutics Announces China NMPA IND Approval for Phase II Clinical Trial of saRNA Therapy RAG-01 in Non-Muscle Invasive Bladder Cancer

March 19, 2026
Ractigen Therapeutics Announces First Patient Dosed in Phase II Clinical Trial of RAG-17 for SOD1-ALS

January 13, 2026
/DISREGARD RELEASE: Ractigen Therapeutics/

December 13, 2025
Ractigen Therapeutics Doses First Patient in IIT Study of RAG-18, a Potential Game-Changing saRNA Therapeutic for Duchenne Muscular Dystrophy

December 13, 2025
Ractigen Therapeutics Doses First Patient in IIT Study of RAG-18 for Duchenne Muscular Dystrophy

December 13, 2025